Jnana Therapeutics is a biotechnology startup that operates in the pharmaceutical industry. The company focuses on the discovery and development of new drugs using a next-generation chemoproteomics platform, known as the RAPID platform. This platform allows Jnana to create small molecule medicines at a faster and more efficient rate than traditional methods.

The company's primary target market is patients in need of new treatments for various diseases. Jnana is currently working on first- and best-in-class therapies for phenylketonuria (PKU), a rare genetic disorder, as well as a wide range of immune-mediated diseases and cancers.

Jnana's business model revolves around the development of these new drugs and therapies. Once a drug is developed and approved, it can be sold to healthcare providers and patients. The company also explores partnerships to expand its reach and capabilities.

In addition to its drug development efforts, Jnana also participates in healthcare and investor conferences to present its progress and attract potential investors. The company also offers opportunities for professionals to join their team and contribute to their mission of advancing drug discovery.

Keywords: Biotechnology, Pharmaceutical Industry, Drug Discovery, Chemoproteomics, RAPID Platform, Small Molecule Medicines, Phenylketonuria (PKU), Immune-Mediated Diseases, Cancer Therapies, Healthcare Conferences.